What role did dr. paul cox hold at neurocept and during which years?

1. What the sources actually say about Paul Cox’s institutional role

Multiple institutional and media pages identify Paul Alan Cox as executive director of Brain Chemistry Labs (the research program of the Institute for Ethnomedicine) in Jackson Hole, Wyoming ^{[1] [2]}. A long Fortune profile about Cox’s neurodegenerative‑disease research also situates him in Jackson Hole and describes his leadership of a small lab there ^[3]. These citations consistently tie Cox to Brain Chemistry Labs and the Institute for Ethnomedicine rather than to an entity called “Neurocept” ^{[1] [2] [3]}.

2. What the sources say (and do not say) about “Neurocept”

None of the provided materials mention a company or organization named Neurocept in connection with Paul Alan Cox. The documents focus on Brain Chemistry Labs / Institute for Ethnomedicine and Cox’s ethnobotany and neurodegenerative‑disease work; they do not document any role at Neurocept or give dates for such an appointment ^{[4] [5] [3] [1] [2]}. Therefore it is not supported by the supplied reporting to state that Cox held a role at Neurocept or to assign years to such a role.

3. Why confusion could arise between organizations and roles

Cox’s career includes multiple institutional affiliations—academic posts, Seacology, the National Tropical Botanical Garden, and the Institute for Ethnomedicine/Brain Chemistry Labs—and media coverage sometimes uses “Brain Chemistry Labs,” “Institute for Ethnomedicine,” or similar labels interchangeably ^{[4] [5] [1]}. That institutional plurality can generate misattribution if a name like “Neurocept” is introduced from outside the cited material. The available sources do not show Cox employed by a private biotech named Neurocept; they consistently portray him as leading a nonprofit research group ^{[1] [2]}.

4. What we can say about timeframe from the available reporting

The supplied sources place Cox actively leading Brain Chemistry Labs and conducting translational research into ALS, Alzheimer’s and Parkinson’s across recent years: for example, a Fortune feature profiles his work from the Jackson Hole lab as of 2018 and later reporting around 2023–2024 continues to describe him as executive director or leader of Brain Chemistry Labs ^{[3] [1] [2]}. However, none of the provided items state the precise year he began or (if applicable) ended a leadership title, nor do they document employment at Neurocept ^{[3] [1] [2]}.

5. Competing interpretations and reporting gaps

Sources consistently label Cox “executive director” of Brain Chemistry Labs ^{[1] [2]} and describe him as director or leader in other institutional contexts ^[5]. But because the provided materials do not mention Neurocept at all, two possibilities remain: either Cox never held a role at Neurocept (supported indirectly by silence across these profiles), or Cox did hold such a role but that detail is absent from the supplied documentation. The correct journalistic posture is to report what is documented (Brain Chemistry Labs leadership) and note the absence of evidence for Neurocept in the current reporting ^{[3] [1] [2]}.

6. What to do next to resolve the question definitively

To determine whether Cox held a role at Neurocept and during which years, consult primary corporate records, Neurocept’s website or press releases, SEC or state business filings, or direct statements from Cox or Neurocept. Those items are not among the provided sources; therefore they cannot be cited here. As of the available reporting, Cox’s verifiable leadership role is with Brain Chemistry Labs/Institute for Ethnomedicine ^{[1] [2] [3]}.

Limitations: This analysis relies solely on the supplied search results and cites only them. If you can provide a specific Neurocept source or allow a lookup beyond these items, I will update this finding with direct citations.